Value of red blood cell distribution width-to-platelet ratio, platelet-to-lymphocyte ratio, and neutrophil-to-lymphocyte ratio in predicting compensated liver cirrhosis in patients with chronic hepatitis C

Na YANG; Hua HE; Tianye ZHAO; Xuerong TAO; Yanhua WU; Jing JIANG

doi:10.3969/j.issn.1001-5256.2021.06.021

Volume 37 Issue 6

Jun. 2021

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2021 > 37(6): 1319-1325

PDF( 1977 KB)

Value of red blood cell distribution width-to-platelet ratio, platelet-to-lymphocyte ratio, and neutrophil-to-lymphocyte ratio in predicting compensated liver cirrhosis in patients with chronic hepatitis C

DOI: 10.3969/j.issn.1001-5256.2021.06.021

Division of Clinical Research, First Hospital of Jilin University, Changchun 130021, China

Research funding:

(2017YFC0907405);

(20200403098SF);

Received Date: 2021-02-24
Accepted Date: 2021-04-23
Published Date: 2021-06-20

Abstract

Abstract

Objective To investigate the value of red blood cell distribution width-to-platelet ratio (RPR), platelet-to-lymphocyte ratio (PLR), and neutrophil-to-lymphocyte ratio (NLR) in predicting chronic hepatitis C (CHC)-related compensated liver cirrhosis by comparing serological markers between CHC patients and patients with compensated hepatitis C cirrhosis. Methods The patients with CHC in two townships of Fuyu County were screened for liver cirrhosis and liver cancer from September to December in 2019 and 2020, respectively. General information was collected; HCV RNA quantification, liver function, and routine blood test results were measured; liver transient elastography and abdominal ultrasound were performed at the same time. RPR, PLR, NLR, fibrosis-4 (FIB-4), and aspartate aminotransferase-to-platelet ratio index (APRI) were calculated. The Mann-Whiney U test was used for comparison between groups. The chi-square test was used for comparison of categorical data between groups. The receiver operating characteristic (ROC) curve was plotted to determine the optimal cut-off values of RPR and PLR. A multivariate unconditional logistic regression analysis was used to investigate the risk factors for CHC-related liver cirrhosis. The linear regression trend test was used to investigate the changing trend of RPR, PLR, FIB-4, and APRI in hepatitis C patients with different fibrosis stages. Results A total of 968 CHC patients were enrolled, among whom 123 (12.7%) were diagnosed with compensated liver cirrhosis (liver cirrhosis group). Compared with the CHC group, the liver cirrhosis group had a significant increase in RPR and a significant reduction in PLR (P < 0.001). The multivariate logistic regression analysis showed that age > 60 years (odds ratio [OR]=1.79, 95% confidence interval [CI]: 1.12-2.86, P=0.015), albumin < 40 g/L (OR=10.40, 95% CI: 3.47-31.18, P < 0.001), RPR > 0.081 (OR=3.83, 95% CI: 2.19-6.69, P < 0.001), PLR < 91.11 (OR=2.25, 95% CI: 1.31-3.89, P=0.004), FIB-4 > 3.25 (OR=3.14, 95% CI: 1.74-5.67, P < 0.001), and APRI > 2 (OR=3.60, 95% CI: 1.10-11.78, P=0.035) were associated with the development of CHC-related compensated liver cirrhosis. With the aggravation of liver fibrosis, RPR, FIB-4, and APRI gradually increased and PLR gradually decreased (all P < 0.001). Conclusion RPR and PLR are associated with the development and fibrosis progression of CHC-related compensated liver cirrhosis. Elderly patients with CHC (age > 60 years) should be monitored for the changes in albumin and liver fibrosis indicators, and RPR and PLR should also be monitored regularly to identify liver cirrhosis in the early stage, give timely treatment, and reduce the incidence rate of liver cancer.
- Hepatitis C,
- Liver Cirrhosis,
- Red Blood Cell,
- Mean Platelet Volume,
- Neutrophil-Lymphocyte Ratio

FullText(HTML)

References(35)

References

[1]	CHEN YS, LI L, CUI FQ, et al. A sero-epidemiological study on hepatitis C in China[J]. Chin J Epidemiol, 2011, 32(9): 888-891. DOI: 10.3760/cma.j.issn.0254-6450.2011.09.009. 陈园生, 李黎, 崔富强, 等. 中国丙型肝炎血清流行病学研究[J]. 中华流行病学杂志, 011, 2(9): 888-891. DOI: 10.3760/cma.j.issn.0254-6450.2011.09.009.
[2]	DUAN Z, JIA JD, HOU J, et al. Current challenges and the management of chronic hepatitis C in mainland China[J]. J Clin Gastroenterol, 2014, 48(8): 679-686. DOI: 10.1097/MCG.0000000000000109.
[3]	MCGLYNN KA, PETRICK JL, EL-SERAG HB. Epidemiology of hepatocellular carcinoma[J]. Hepatology, 2021, 73(Suppl 1): 4-13. DOI: 10.1002/hep.31288.
[4]	FATTOVICH G, STROFFOLINI T, ZAGNI I, et al. Hepatocellular carcinoma in cirrhosis: Incidence and risk factors[J]. Gastroenterology, 2004, 127(5 Suppl 1): s35-s50. DOI: 10.1053/j.gastro.2004.09.014.
[5]	KUMAR R, TEO EK, HOW CH, et al. A practical clinical approach to liver fibrosis[J]. Singapore Med J, 2018, 59(12): 628-633. DOI: 10.11622/smedj.2018145.
[6]	GRGUREVIC I, BOZIN T, MADIR A. Hepatitis C is now curable, but what happens with cirrhosis and portal hypertension afterwards?[J]. Clin Exp Hepatol, 2017, 3(4): 181-186. DOI: 10.5114/ceh.2017.71491.
[7]	KONG Y, SUN Y, ZHOU J, et al. Early steep decline of liver stiffness predicts histological reversal of fibrosis in chronic hepatitis B patients treated with entecavir[J]. J Viral Hepat, 2019, 26(5): 576-585. DOI: 10.1111/jvh.13058.
[8]	STASI C, MILANI S. Evolving strategies for liver fibrosis staging: Non-invasive assessment[J]. World J Gastroenterol, 2017, 23(2): 191-196. DOI: 10.3748/wjg.v23.i2.191.
[9]	CARMONA I, CORDERO P, AMPUERO J, et al. Role of assessing liver fibrosis in management of chronic hepatitis C virus infection[J]. Clin Microbiol Infect, 2016, 22(10): 839-845. DOI: 10.1016/j.cmi.2016.09.017.
[10]	ZHENG J, CAI J, LI H, et al. Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio as prognostic predictors for hepatocellular carcinoma patients with various treatments: A Meta-analysis and systematic review[J]. Cell Physiol Biochem, 2017, 44(3): 967-981. DOI: 10.1159/000485396.
[11]	STOJKOVIC LALOSEVIC M, PAVLOVIC MARKOVIC A, STANKOVIC S, et al. Combined diagnostic efficacy of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and mean platelet volume (MPV) as biomarkers of systemic inflammation in the diagnosis of colorectal cancer[J]. Dis Markers, 2019, 2019: 6036979. DOI: 10.1155/2019/6036979.
[12]	PAN YC, JIA ZF, CAO DH, et al. Preoperative lymphocyte-to-monocyte ratio (LMR) could independently predict overall survival of resectable gastric cancer patients[J]. Medicine (Baltimore), 2018, 97(52): e13896. DOI: 10.1097/MD.0000000000013896.
[13]	LAI Q, CASTRO SANTA E, RICO JURI JM, et al. Neutrophil and platelet-to-lymphocyte ratio as new predictors of dropout and recurrence after liver transplantation for hepatocellular cancer[J]. Transpl Int, 2014, 27(1): 32-41. DOI: 10.1111/tri.12191.
[14]	LIN L, YANG F, WANG Y, et al. Prognostic nomogram incorporating neutrophil-to-lymphocyte ratio for early mortality in decompensated liver cirrhosis[J]. Int Immunopharmacol, 2018, 56: 58-64. DOI: 10.1016/j.intimp.2018.01.007.
[15]	MILAS GP, KARAGEORGIOU V, CHOLONGITAS E. Red cell distribution width to platelet ratio for liver fibrosis: A systematic review and meta-analysis of diagnostic accuracy[J]. Expert Rev Gastroenterol Hepatol, 2019, 13(9): 877-891. DOI: 10.1080/17474124.2019.1653757.
[16]	MENG X, WEI G, CHANG Q, et al. The platelet-to-lymphocyte ratio, superior to the neutrophil-to-lymphocyte ratio, correlates with hepatitis C virus infection[J]. Int J Infect Dis, 2016, 45: 72-77. DOI: 10.1016/j.ijid.2016.02.025.
[17]	ZHAO Z, LIU J, WANG J, et al. Platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR) are associated with chronic hepatitis B virus (HBV) infection[J]. Int Immunopharmacol, 2017, 51: 1-8. DOI: 10.1016/j.intimp.2017.07.007.
[18]	PENG Y, LI Y, HE Y, et al. The role of neutrophil to lymphocyte ratio for the assessment of liver fibrosis and cirrhosis: a systematic review[J]. Expert Rev Gastroenterol Hepatol, 2018, 12(5): 503-513. DOI: 10.1080/17474124.2018.1463158.
[19]	Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of hepatitis C (2019 version)[J]. J Clin Hepatol, 2019, 35(12): 2670-2686. DOI: 10.3969/j.issn.1001-5256.2019.12.008. 中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2670-2686. DOI: 10.3969/j.issn.1001-5256.2019.12.008.
[20]	Chinese Society of Hepatology, Chinese Medical Association. Chinese guidelines on the management of liver cirrhosis[J]. J Clin Hepatol, 2019, 35(11): 2408-2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006. 中华医学会肝病学分会. 肝硬化诊治指南[J]. 临床肝胆病杂志, 2019, 35(11): 2408-2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006.
[21]	TSOCHATZIS EA, BOSCH J, BURROUGHS AK. Liver cirrhosis[J]. Lancet, 2014, 383(9930): 1749-1761. DOI: 10.1016/S0140-6736(14)60121-5.
[22]	D'AMICO G, GARCIA-TSAO G, PAGLIARO L. Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies[J]. J Hepatol, 2006, 44(1): 217-231. DOI: 10.1016/j.jhep.2005.10.013.
[23]	YANG M, PARIKH ND, LIU H, et al. Incidence and risk factors of hepatocellular carcinoma in patients with hepatitis C in China and the United States[J]. Sci Rep, 2020, 10(1): 20922. DOI: 10.1038/s41598-020-77515-y.
[24]	BIAN DD, JIANG YY, ZHOU HY, et al. Current status of antiviral therapy for hepatitis C related cirrhosis and hepatocellular carcinoma in mainland China[J]. Chin J Gastroenterol Hepatol, 2019, 28(7): 750-754. DOI: 10.3969/j.issn.1006-5709.2019.07.007. 卞丹丹, 蒋莹莹, 周海洋, 等. 中国大陆丙肝相关肝硬化及肝癌患者抗病毒治疗现状调查[J]. 胃肠病学和肝病学杂志, 2019, 28(7): 750-754. DOI: 10.3969/j.issn.1006-5709.2019.07.007.
[25]	CAO MM, CHEN WQ. Research progress of liver cancer screening[J]. China Cancer, 2020, 29(12): 925-932. DOI: 10.11735/j.issn.1004-0242.2020.12.A007. 曹毛毛, 陈万青. 肝癌筛查研究进展[J]. 中国肿瘤, 2020, 29(12): 925-932. DOI: 10.11735/j.issn.1004-0242.2020.12.A007.
[26]	LIPPI G, PLEBANI M. Red blood cell distribution width (RDW) and human pathology. One size fits all[J]. Clin Chem Lab Med, 2014, 52(9): 1247-1249. DOI: 10.1515/cclm-2014-0585.
[27]	TEKCE H, KIN TEKCE B, AKTAS G, et al. The evaluation of red cell distribution width in chronic hemodialysis patients[J]. Int J Nephrol, 2014, 2014: 754370. DOI: 10.1155/2014/754370.
[28]	JELKMANN W. Proinflammatory cytokines lowering erythropoietin production[J]. J Interferon Cytokine Res, 1998, 18(8): 555-559. DOI: 10.1089/jir.1998.18.555.
[29]	WANG ZD, WU H. Pathogenesis and treatment of thrombocytopenia in patients with liver cirrhosis[J]. Prac J Clin Med, 2020, 17(1): 212-215. DOI: 10.3969/j.issn.1672-6170.2020.01.065. 王治东, 吴浩. 肝硬化患者血小板减少的发病机制及治疗[J]. 实用医院临床杂志, 2020, 17(1): 212-215. DOI: 10.3969/j.issn.1672-6170.2020.01.065.
[30]	KUROKAWA T, OHKOHCHI N. Platelets in liver disease, cancer and regeneration[J]. World J Gastroenterol, 2017, 23(18): 3228-3239. DOI: 10.3748/wjg.v23.i18.3228.
[31]	LI X, XU H, GAO P. Red Blood Cell Distribution width-to-platelet ratio and other laboratory indices associated with severity of histological hepatic fibrosis in patients with autoimmune hepatitis: A retrospective study at a single center[J]. Med Sci Monit, 2020, 26: e927946. DOI: 10.12659/MSM.927946.
[32]	HE Q, HE Q, QIN X, et al. The relationship between inflammatory marker levels and hepatitis C virus severity[J]. Gastroenterol Res Pract, 2016, 2016: 2978479. DOI: 10.1155/2016/2978479.
[33]	GOMEZ D, FARID S, MALIK HZ, et al. Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma[J]. World J Surg, 2008, 32(8): 1757-1762. DOI: 10.1007/s00268-008-9552-6.
[34]	LI X, WANG L, GAO P. Chronic hepatitis C virus infection: Relationships between inflammatory marker levels and compensated liver cirrhosis[J]. Medicine (Baltimore), 2019, 98(39): e17300. DOI: 10.1097/MD.0000000000017300.
[35]	ABDEL-RAZIK A, MOUSA N, BESHEER T A, et al. Neutrophil to lymphocyte ratio as a reliable marker to predict insulin resistance and fibrosis stage in chronic hepatitis C virus infection[J]. Acta Gastroenterol Belg, 2015, 78(4): 386-392. DOI: 10.1109/APS.2006.1711016.

Relative Articles

Supplements(0)

Cited By

Cited by

Periodical cited type(12)

1.	阳丽华，梁英，刘仁峰，刘志昂. 甲状腺癌与甲状腺肿患者相关实验室指标的比较分析. 甘肃医药. 2025(01): 53-55+59 .
2.	何艳婷，苏有盛，叶宇龙. ALBI联合NLR预测肝硬化合并食管胃底静脉曲张破裂出血的作用. 广州医药. 2025(03): 387-392 .
3.	张海苗. HBV感染原发性肝癌患者血常规指标的检测意义. 包头医学院学报. 2024(02): 67-71 .
4.	戴倩梅，丁体龙，代雪枫，于莉，陈策. 高敏丙型肝炎病毒核糖核酸在丙型肝炎中的诊断价值. 检验医学与临床. 2024(04): 487-490 .
5.	李晓宇，黄秀香，叶迎宾. 血清壳多糖酶3样蛋白1和PLT的比值与FIB-4指数在慢性乙型肝炎轻、中度诊断效价的比较. 标记免疫分析与临床. 2024(09): 1693-1697 .
6.	何萍，徐瑞，华秋菊，姜璐，王维平. 红细胞分布宽度与血小板比值对终末期肾病维持性血液透析患者动静脉内瘘失功的预测分析. 中国医师进修杂志. 2024(11): 988-994 .
7.	岳丽，孙佳瑶，刘龙芳. 脑小血管病患者外周血GPR30 mRNA、PLR、NPAS4表达及与认知功能、短期预后的关系. 临床误诊误治. 2023(01): 69-74 .
8.	杨杨，刘付弟，曾方林. 人类免疫缺陷病毒/乙型肝炎病毒合并感染者CD4~+T细胞计数和乙型肝炎病毒复制、中性粒细胞与淋巴细胞比值水平的相关性. 中国医药导报. 2023(10): 145-148 .
9.	王跃帮，常珊碧，王梦林，崔倩，裴兵. RLR在HBV相关性肝硬化诊断中的应用. 热带医学杂志. 2023(10): 1451-1455 .
10.	邱建华. PLT联合凝血功能检测对早期肝硬化的诊断价值分析. 现代诊断与治疗. 2023(22): 3433-3435 .
11.	赵霄君，谢建刚，段楚君，刘善收，王倩梅，思艺，王林潇，吴丹，王一帆，李俊杰. 血常规指标与脓毒症患者短期预后的相关性研究. 临床误诊误治. 2022(08): 73-77 .
12.	邵林楠，张树婷，王霓，周世航，刘铭. 血细胞各比值对慢性丙型肝炎病毒患者肝纤维化程度的评估. 临床血液学杂志. 2022(12): 874-877 .

Other cited types(7)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(2) / Tables(4)

Get Citation

PDF

XML

Article Metrics

Article views (1026) PDF downloads(93)

Value of red blood cell distribution width-to-platelet ratio, platelet-to-lymphocyte ratio, and neutrophil-to-lymphocyte ratio in predicting compensated liver cirrhosis in patients with chronic hepatitis C

DOI: 10.3969/j.issn.1001-5256.2021.06.021